The Gavathiotis laboratory aims to elucidate and target mechanisms of protein-protein interaction in cell death and cell surivival that are deregulated in cancer and other diseases. Our goal is to translate our understanding of biological processes into novel pharmacologic strategies and prototype therapeutics that can lead to cures. To achieve our goal, we take an interdisciplinary approach using chemical synthesis, structure-based design, structural biology, biochemistry, cellular and in vivo pharmacology.
Dr. Gavathiotis and Dr. Kitsis Receive the 2015 AHA Collaborative Sciences Award on developing a novel drug to limit heart damage during myocardial infarction (heart attack) Press release
Dr. Gavathiotis will facilitate a Leducq Transatlantic Network of Excellence with colleagues from Einstein, Rutgers New Jersey Medical School, Howard Hughes Medical Institute/University of Texas Southwestern, Kings College (London, UK), Gustave Roussy (France), University of Padua (Italy), and Maastricht University (Netherlands) for developing novel modulators of autophagy. Press release
Tom identified a new binding site on BAX that controls BAX inhibition from the BCL-2 BH4 helix in a recent collaborative paper published in Molecular Cell!
Dr. Gavathiotis was awarded the 2014 Young Chemical Biologist Award and gave a podium presentation during the Rising Stars of Chemical Biology Session in the 3rd Annual Conference of the International Chemical Biology Society
Two papers in the European Journal of Medicinal Chemistry and Marine Drugs report our collaborative efforts to identify Mcl-1 selective inhibitors and dual Mcl-1/Bcl-xL inhibitors based on the marinopyrole scaffold.